TALS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TALS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Talaris Therapeutics does not have enough data to calculate 5-Year ROIIC %.
The historical data trend for Talaris Therapeutics's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Talaris Therapeutics Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
5-Year ROIIC % | - | - | - | - |
Talaris Therapeutics Quarterly Data | |||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
5-Year ROIIC % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Talaris Therapeutics's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Talaris Therapeutics's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Talaris Therapeutics's 5-Year ROIIC % falls into.
Talaris Therapeutics's 5-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:
5-Year ROIIC % | = | 5-Year Incremental Net Operating Profit After Taxes (NOPAT)** | / | 5-Year Incremental Invested Capital** |
= | ( -76.477 (Dec. 2022) - (Dec. 2017) ) | / | ( 12.578 (Dec. 2022) - (Dec. 2017) ) | |
= | / | |||
= | N/A%*** |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Talaris Therapeutics (NAS:TALS) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Thank you for viewing the detailed overview of Talaris Therapeutics's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cariad Chester | director | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Yung H. Chyung | officer: Chief Medical Officer | C/O SCHOLAR ROCK, 620 MEMORIAL DR., 2ND FLOOR, CAMBRIDGE MA 02139 |
Caley Castelein | director | THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104 |
W Bradford Middlekauff | officer: CBO, GC and Secretary | 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922 |
Aaron Kantoff | director | C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH |
Sandeep Chidambar Kulkarni | director, officer: CEO | 92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027 |
Kevin Bruce Johnson | officer: Chief Regulatory Officer | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Ryan F. Robinson | officer: Interim CFO | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Parvinder Thiara | director | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Susan Dana Jones | officer: Chief Technology Officer | C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010 |
Suzanne Ildstad | director, 10 percent owner, officer: Chief Scientific Officer | C/O TALARIS THERAPEUTICS, INC., 93 WORCESTER STREET, SUITE 120, WELLESLEY MA 02481 |
Scott Requadt | director, officer: See Remarks | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
Francois Nader | director | 550 HILLS DRIVE, BEDMINSTER NJ 07921 |
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Longitude Capital Partners Iii, Llc | 10 percent owner | 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025 |
From GuruFocus
By Marketwired • 10-06-2023
By GuruFocusNews GuruFocusNews • 07-10-2022
By PRNewswire • 08-22-2023
By Marketwired • 10-17-2023
By Marketwired • 06-22-2023
By Value_Insider Value_Insider • 11-10-2022
By Marketwired • 07-28-2023
By Marketwired • 08-21-2023
By PRNewswire • 08-15-2023
By Marketwired • 06-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.